Improvement of Women's Health After Allogeneic Stem Cell Transplantation

Recruiting now

Conditions studied: GVHD, Chronic

In brief

The aim of this prospective research project is to better understand vulvovaginal cGVHD to improve care of allografted women. The expected outcomes include better knowledge of the incidence and manifestations of vulvovaginal cGVHD, risk factors, response to treatments and impact on sexual health of allotransplanted female patients. The knowledge acquired will allow transplant clinicians to make more precise recommendations for gynecological management of future allografted women.

Key facts

Study ID

NCT06279676

Run by

Ciusss de L'Est de l'Île de Montréal

People needed

100

Starts

2024-08-27

Expected to finish

2028-12-01

Last updated by the study team

2026-03-18

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• All women aged 18 and over who will receive a first allogeneic HSCT (bone marrow, peripheral blood stem cells from a related, unrelated (including cord blood) or haploidentical donor) at the CIUSSS-EMTL. Recruitment will begin when the project receives ethical approval. Recruitment period will be of 2 to 3 years.

You may not qualify if…

• Those who receive a second HSCT allograft.
• Those who receive an autologous transplant.
• Inability to give informed consent.
• Unable to communicate in French or English.
• Any other reason which, according to the investigators, makes it preferable for a patient not to participate.

Where it is running

• CIUSSS de l'Est-de-l'Ile-de-Montréal / Hôpital Maisonneuve-Rosemont — Montreal, Quebec, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.